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Regardless of the etiology or pathogenesis, chronic liver
disease remains a major health issue worldwide and a
significant cause of morbidity and mortality particularly
when its common outcomes, i.e., liver cirrhosis and primary
liver cancer, are observed. As a result, liver diseases
cumulatively account for enormous costs, as well repre-
sented by health-state utilities and subsequent cost-utility
analysis [1]. Table 1 illustrates the available data on disease
prevalence, economic costs, and need for liver transplanta-
tion in the US. From a clinical standpoint, the majority of
conditions remain asymptomatic until advanced stages are
established. From a pathogenetic standpoint, all chronic
liver diseases manifest one common trait, that is the
involvement of the immune system, and over the past
decade the role of the liver as a critical immunological
center has been established thus overcoming the classical
view of this organ as a mere target of the autoimmune or
immune-mediated injury.
Indeed, the liver is a unique lymphoid organ being the
crossroad at which the majority of antigens enter the
organism. The liver is located between the gastrointestinal
system and the systemic venous circulation, and every
minute approximately one third of the total blood volume
passes through the liver delivering over 100 million
lymphocytes in 1 day. As a result, the liver must provide
an accurate balance between generating tolerance to self as
well as to non-pathogenic molecules and microorganisms,
and producing an appropriate immune response to patho-
gens. Furthermore, the mechanisms by which hepatitis
viruses cause a liver injury also involve the liver immuno-
logical milieu which ultimately constitutes per se an
important element in the pathogenesis of chronic inflam-
matory liver diseases, either infectious or autoimmune. The
history of the existence of mechanisms capable to induce
liver tolerance well illustrates this scenario starting with the
first data on the tolerogenic properties of the liver in 1969
when the liver allograft acceptance across an MHC
mismatch in the pig was reported [2]. Following these
earlier studies, numerous authors have suggested over the
decades possible mechanisms underlying hepatic tolerance
to intestinally derived antigens or the mechanisms of virus-
induced liver injury, yet none of the hypotheses has gained
sufficient support for universal acceptance.
As previously mentioned, the lymphoid liver is expected
to act in two separate yet closely correlated ways as the first
line of defense against invasion by intestinally derived
infectious agents or as a site of tolerance. This question
becomes particularly relevant in clinical conditions wherein
the machinery does not function properly, as in cases of
chronic hepatitis virus infections in which an effector
immune response is directed unsuccessfully against virally
infected hepatocytes, or in liver autoimmunity wherein
tolerance to self molecules is inefficient. The present issue
of the Seminars in Immunopathology will attempt to
provide a comprehensive overview of what we currently
know on these complex mechanisms. This issue will not
discuss the enormous field of the immunology of viral
hepatitis; this has been a difficult editorial choice and does
not imply a lack of interest in the field. Indeed, new and
exciting observations in chronic viral hepatitis C have been
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and therapeutic applications [7, 8] while data on hepatitis B
virus also appear promising for novel therapeutic develop-
ments [9–11]. On the other hand, we have decided to
dedicate the first part of the issue to general issues such as
liver microanatomy and architecture. The role of specific
cell populations such as the bile duct and the hematopoietic
stem cells will be also discussed in dedicated articles to
reflect the importance of these cells supported by the most
recent data [12–22]. Further, the development of fibrosis is
the common outcome of all chronic liver diseases and Dr.
Marra and colleagues will illustrate the current knowledge
on the role of mononuclear immune cells in determining
inflammation and fibrosis, as suggested by the most recent
literature [23]. The second part of this issue will be
dedicated to specific clinical entities, including biliary
atresia, chronic autoimmune hepatitis, primary sclerosing
cholangitis, and primary biliary cirrhosis. Finally, a special
contributionwillbededicatedtothe conditionthatisexpected
to constitute the major chronic liver disease challenge in the
next future, that is, non-alcoholic fatty liver disease and its
progressing subtype steatohepatitis. Of note, the pathogenesis
of this condition has been subject to a tremendous research
effort over the past months [6, 23–39] and we foresee that
such interest will increase in the future.
Some outlines from the present days are to provide a
snapshot of the several peculiarities of the lymphoid liver.
As an example, the liver exhibits unique cytoarchitectural
features; there is consignment of proliferating T cells to
activation-induced cell death; and there are placating
activities in the liver of cell populations such as NKT,
Treg, and others. Considering effector activities, there is
input from elements of the innate system, neutralizing
antibodies, and the well-studied CD4+ helper and CD8+
cytolytic T cell populations that normally provide sturdy
responses to intruders ranging from hepatitis viruses to
multicellular parasites. However, the necessarily fine
immunotuning in the liver may constitute a risk for
occurrence of autoreactivity or the occupancy of liver cells
by hepatitis B and C viruses and metabolic disturbances
such as lipid deposition that alter the normal liver cell
structure to provoke profound cytokine and chemokine
activation.
The example of primary biliary cirrhosis may well
illustrate these concepts as data on the disease pathogenesis
are becoming more convincing [40]. The presence of serum
autoantibodies and autoreactive T and B cells, in conjunc-
tion with the coexistence of other autoimmune diseases,
implies an autoimmune pathogenesis for primary biliary
cirrhosis while experimental data suggest an important role
for the bile duct cell in mediating or facilitating the
autoimmune injury. However, the mechanisms for disease
onset remain to be determined with putative contributors
such as innate immunity or microRNA being studied only
recently [41–43].
Another important issue in liver immunology is related
to liver transplantation, the only therapeutic option in end-
stage liver diseases. Clinical practice has witnessed several
advancements in this field, yet legislation and regulations
have often failed to keep the pace with the advances in
healthcare technology [44]. Current estimates suggest that
over 15,000 people in the US await for a liver transplant
and this number has been steadily increasing over the past
few years while it has been estimated that nearly 4,000
patients are added to the list each month. Conversely, organ
donation and transplantation rates recently decreased in the
US as 27,958 organ transplant procedures were performed
in 2008 (declined by 1.42% from 2007) according to
UNOS data. The lymphoid liver is obviously central to the
issue of liver transplantation in terms of donor liver and
recipient graft tolerance. Two major examples come from
the recent observation of occult hepatitis B infection [45]
Prevalence [47] Expenditures
(US$ million) [47]
Liver transplantations
(% of total) [48]
Adult disease
Alcoholic liver disease 7.4% 26,400 18%
a
Non-alcoholic fatty liver disease 20% – 11%
b
Hepatitis C 1.8% 1,300 29%
a
Hepatitis B 4.9% – 2%
Primary biliary cirrhosis 0.04% 115 9%
c
Primary sclerosing cholangitis 0.004% ––
Autoimmune hepatitis 2%
Hepatocellular carcinoma 0.004% 1,300 13%
Pediatric disease
Biliary atresia –– 3%
Wilson disease 0.003% ––
Table 1 Prevalence, yearly
economic cost, and liver trans-
plantation of adult and pediatric
liver diseases in the US
Of note, several data are
currently missing due to the lack
of solid population-based
studies while in some cases
multiple etiologies coexist
aPatients with mixed etiology
(alcohol and HCV) are included
in both categories
bCases include also cryptogenic
cirrhosis
cThe percentage refers to cases
of cholestatic liver disease
(PBC and PSC)
280 Semin Immunopathol (2009) 31:279–282which has significantly mined the concept of ‘healthy’
organ donor and the most recent data suggesting that liver
immunology is critical to graft tolerance or rejection [46].
Indeed, we hope that the answers to the numerous open
questions in liver immunology will be closer following this
Seminars issue.
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